Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A. Switzer; David C. Hess; Adviye Ergul; Jennifer L. Waller; Livia S. MacHado; Vera Portik-Dobos; L. Creed Pettigrew; Wayne M. Clark; Susan C. Fagan

doi:10.1161/STROKEAHA.111.618215

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A. Switzer, David C. Hess, Adviye Ergul, Jennifer L. Waller, Livia S. MacHado, Vera Portik-Dobos, L. Creed Pettigrew, Wayne M. Clark, Susan C. Fagan

Research output: Contribution to journal › Article › peer-review

115 Scopus citations

Abstract

Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

Original language	English
Pages (from-to)	2633-2635
Number of pages	3
Journal	Stroke
Volume	42
Issue number	9
DOIs	https://doi.org/10.1161/STROKEAHA.111.618215
State	Published - Sep 2011

Keywords

acute stroke
inflammation
neuroprotection

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

Access to Document

10.1161/STROKEAHA.111.618215

Cite this

@article{23569f248a2d4265b8ec2e966334d858,

title = "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke",

abstract = "Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.",

keywords = "acute stroke, inflammation, neuroprotection",

author = "Switzer, {Jeffrey A.} and Hess, {David C.} and Adviye Ergul and Waller, {Jennifer L.} and MacHado, {Livia S.} and Vera Portik-Dobos and Pettigrew, {L. Creed} and Clark, {Wayne M.} and Fagan, {Susan C.}",

year = "2011",

month = sep,

doi = "10.1161/STROKEAHA.111.618215",

language = "English",

volume = "42",

pages = "2633--2635",

number = "9",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

AU - Switzer, Jeffrey A.

AU - Hess, David C.

AU - Ergul, Adviye

AU - Waller, Jennifer L.

AU - MacHado, Livia S.

AU - Portik-Dobos, Vera

AU - Pettigrew, L. Creed

AU - Clark, Wayne M.

AU - Fagan, Susan C.

PY - 2011/9

Y1 - 2011/9

N2 - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

AB - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

KW - acute stroke

KW - inflammation

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=80052415005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052415005&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.618215

DO - 10.1161/STROKEAHA.111.618215

M3 - Article

C2 - 21737808

AN - SCOPUS:80052415005

SN - 0039-2499

VL - 42

SP - 2633

EP - 2635

JO - Stroke

JF - Stroke

IS - 9

ER -

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this